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Abstract
Background: In the assessment of a pituitary mass, objective visual field testing represents a valuable means of
evaluating mass effect, and thus in deciding whether surgical management is warranted.
Case presentation: In this vignette, we describe a 73 year-old lady who presented with a three-week history of
frontal headache, and ‘blurriness’ in the left side of her vision, due to a WHO grade III anaplastic haemangiopericytoma
compressing the optic chiasm. We report how timely investigations, including an iPad-based visual field test
(Melbourne Rapid Field, (MRF)) conducted at the bedside aided swift and appropriate management of the patient.
Conclusions: We envisage such a test having a role in assessing bed-bound patients in hospital where access to
formal visual field testing is difficult, or indeed in rapid testing of visual fields at the bedside to screen for post-
operative complications, such as haematoma.
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Background
History, examination and investigation of a patient with
a suspected pituitary mass should aim not only to iden-
tify the cause of the mass, but also to ascertain if there is
compression of adjacent structures, or clinical features
of pituitary hormone abnormality. In any patient with
signs of mass effect, such as a visual field defect or cra-
nial nerve neuropathy, urgent MRI imaging and consid-
eration of surgical decompression is warranted [1].
Formal assessment of visual fields using standard au-
tomated perimetry is routinely performed in patients
with pituitary tumours to determine the degree of
impairment caused by optic chiasm compression. Such
assessment is necessary in planning the urgency of sur-
gical intervention. However, formal standard automated
perimetry cannot be performed in patients who are
bed-bound, or in situations when visual field testing
equipment is unavailable. Here we report a case in
which a novel visual field test using a portable tablet
device (Melbourne Rapid Field, (MRF)) was used to as-
sess a patient with a pituitary tumour at the bedside.
Case presentation
A 73 year-old presented to Addenbrooke’s Hospital in
Cambridge with a three-week history of frontal headache
and ‘blurriness’ in the left side of her vision. She had no
nausea, vomiting, diplopia, facial pain or paraesthesia,
and had no symptoms of pituitary hormone abnormality
on admission. She had, however, presented 7 months
prior with nausea and vomiting. On this previous admis-
sion, she was found to be hyponatraemic, with a reduced
cortisol of 26 nmol/L and impaired cortisol response to
synacthen (peak 119 nmol/L), and was commenced on
oral hydrocortisone. FSH and LH were within normal
limits and an MRI head showed no obvious mass lesion
within the sella. Her past medical history included long-
standing hypothyroidism, for which she was taking
levothyroxine, iron-deficiency anaemia, and left sacroilitis.
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At presentation, pertinent examination findings
included a reduced visual acuity (6/18 in both eyes giv-
ing 6/12 with pinhole) and bitemporal hemianopia to
confrontation. Further neurological examinations were
unremarkable, and there were no other cranial nerve
abnormalities. Urgent MRI head, pituitary hormone as-
says and Ophthalmology review for formal visual acuity
and visual field testing were requested.
MRI imaging revealed an intrasellar mass with con-
trast enhancement (Fig. 1), which showed significant
enlargement since the previous MRI head carried out 7
months earlier. Pre- and post-contrast images through
the pituitary fossa showed the mass extending super-
iorly into the suprasellar region, where it appeared to
compress the optic chiasm, and inferiorly into the
sphenoid sinus. It had a lobular margin, and measured
34×12×15mm, with homogeneous enhancement post-
contrast. It appeared to extend laterally into the cavern-
ous sinus to lie inseparable from the carotid arteries.
No pituitary tissue could be seen separately from the
mass.
Ophthalmology review took place out-of-hours, when
formal visual field testing was unavailable. Fundoscopy
revealed healthy appearances of the optic disc. Visual
acuity was 6/18 in both eyes. Visual field testing was
performed on an iPad-based tangent perimeter,
(Melbourne Rapid Field (MRF)), which performs fast
thresholding at various locations within 30° of fixation,
and has been validated in a patients with glaucoma [2].
With the iPad tablet screen, measuring 195 × 150 mm,
viewed 33 cm away from the patient, the patient is
instructed to fixate upon a target, and tap their finger on
the screen or keyboard when they see a stimulus.
The MRF test was performed at the bedside of the
patient using an iPad tablet (iPad version 3, Apple,
Cupertino USA) attached to a keyboard, and an eye
occluder. Reliability tests including fixation loss, false
positive and false negative rates were conducted
throughout the test and the patient’s performance was
within reliable limits. The test lasted 4.5 min for each
eye, and confirmed a dense superior bitemporal field
loss with early involvement of the inferior bitemporal
fields (Fig. 2). The visual field loss involved both foveal
visual fields and likely accounted for the drop in visual
acuity.
With MRI imaging and objective visual field meas-
urement confirming compression of the optic chiasm,
neurosurgical intervention was planned, and the pa-
tient started on dexamethasone. Formal Humphrey
24–2 visual field assessment was performed 2 days later
Fig. 1 Sagittal and coronal MRI views, revealing a 34 × 12 × 15 mm intrasellar mass, extending into the sphenoid and cavernous sinuses
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(Figs. 3 and 4) and confirmed a superior bitemporal
visual field loss. Of note, global indices such as mean
deviation and pattern deviation were comparable
between MRF and Humphrey visual field tests. Mean
deviation for the right eye was −9.53 dB (decibels) and
−7.87 dB for MRF and Humphrey visual field respect-
ively, and left eye was −9.19 dB and −8.54 dB respect-
ively. Test time for Humphrey 24–2 field was longer,
taking approximately 8 min per eye.
Two days later, the patient underwent an endonasal
endoscopic resection of the pituitary mass. Histology
revealed a WHO grade III anaplastic haemangioperi-
cytoma, with a high proliferative grade (MIB-1 23%),
pleomorphism and atypical cells. Given these patho-
logical findings, and the high risk of recurrence and
metastasis, FDG PET and bone scans were carried out.
These revealed areas of uptake in the humeri, right
sacral ala and small lymph nodes in the neck. Follow-
ing a multi-disciplinary endocrine team discussion, the
patient was started on a course of radiotherapy (54–
60 Gy over 6 weeks), with a plan for early post-
operative MRI head.
Fig. 2 MRF result for left (a) and right (b) eyes, confirming a dense superior bitemporal field loss, with early inferior bitemporal involvement.
Decibel threshold values are shown, with mean deviation (MD) and pattern deviation (PD) calculated therefrom. Insert at top right is a greyscale
of depth of defect
Fig. 3 Humphrey 24–2 SITA-Standard visual field test result for patient’s left (a) and right (b) eyes, confirming a dense superior bitemporal field
loss, conduced two days after MRF tests
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Two weeks post-operatively, the patient’s visual acuity
had returned to its baseline of 6/9 in the right eye, and
6/6 in left eye (6/4 and 6/5 with pinhole). Repeat visual
field testing using MRF and Humphrey 24–2 assessment
was performed, and both showed marked improvement
in the visual fields consistent with the improved acuity.
Discussion and Conclusions
Tumours within the pituitary gland are common, with
adenomas most prevalent and accounting for approxi-
mately 17% of lesions [3]. Intracranial haemangiopericy-
tomas, first characterised by Stout and Murray in1942
[4], are rare vascular tumours, originating from contract-
ile pericytes that form the walls of meningothelial
capillaries. They are highly aggressive neoplasms, with a
high incidence of recurrence and metastasis [5]. Our
case describes the first reported use of the Melbourne
Rapid Field test in clinical practice to assess visual fields
in a patient with a pituitary mass. In this case, a quick
iPad-based test demonstrated a bitemporal field defect
at the bedside, and allowed appropriate planning for sur-
gical intervention. The test also was able to confirm the
resolution of bitemporal field defect following surgery,
taking 3.5 mins to do so.
This test may have a role in assessing bed-bound pa-
tients in hospital where access to formal visual field
testing is difficult, or indeed in rapid testing of visual
fields at the bedside to screen for post-operative
Fig. 4 Melbourne Rapid Field (left - a, right - b) and Humphrey 24–2 SITA-Standard visual field test result (left - c, right - d), both confirmimg
resolution of visual field defect two weeks post-operatively
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complications, such as haematoma. Use of a keyboard
as in this case, which the patient can tap when they see
a stimulus, limits the visual dexterity needed to per-
form the test, and avoids changes in the alignment and
distance of the iPad relative to the eye.
We envisage the test also being utilised in settings where
formal visual field testing is not readily available, such as
rural areas in developing countries [6], or in the home set-
ting, where visual fields could be monitored in patients
with slow growing pituitary adenomas. Such a setup may
improve the overall experience of regular visual field test-
ing, and alleviate the current difficulties associated with
formal testing currently reported by patients [7].
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